Korro Bio closed at $16.62 on Nov 4, up 4.79%, 54.9% below its 52-week closing high. Volume of 262.9K shares was 1.16× its 20-day average (close to normal).
Split-adjusted performance: +70.3% over one month, +24.6% over six months, -54.9% over one year.
Short interest was 1.7M shares at the Oct 15 settlement, up 3.4% from the prior report (14.8% of float, 9.6 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| KRROKorro Bio | $16.62 | +4.79% | +24.6% | −100.0% | — | — | $244.7M | |
| LFCRLifecore Biomedical | $6.44 | +0.31% | +29.8% | — | −20.9% | — | $244.1M | Compare |
| IMRXImmuneering | $3.76 | +2.17% | −27.6% | — | — | — | $243.5M | Compare |
| LABStandard BioTools | $0.6160 | +0.85% | −36.4% | −0.9% | 69.6% | 1.8 | $243.1M | Compare |
| ABEOAbeona Therapeutics | $4.22 | −0.71% | −29.8% | +2745.0% | −177.4% | — | $241.3M | Compare |
| GLSIGreenwich LifeSciences | $16.35 | +2.70% | −29.1% | — | — | — | $240.0M | Compare |
| CAMPCAMP4 Therapeutics | $3.74 | −2.35% | −7.9% | +18.8% | −1884.8% | — | $234.7M | Compare |
| VNDAVanda Pharmaceuticals | $3.88 | +3.47% | −47.8% | +24.1% | −32.3% | — | $234.6M | Compare |
| SIGASIGA Technologies | $3.15 | +1.29% | −33.0% | −49.5% | 30.4% | — | $226.3M | Compare |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
